

# Cecilia J Proietti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/418987/publications.pdf>

Version: 2024-02-01

28  
papers

1,182  
citations

394421

19  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1519  
citing authors

#	ARTICLE	IF	CITATIONS
1	TNF $\alpha$ acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF- $\kappa$ B-dependent pathways. <i>Experimental Cell Research</i> , 2008, 314, 509-529.	2.6	135
2	Progesterins Induce Transcriptional Activation of Signal Transducer and Activator of Transcription 3 (Stat3) via a Jak- and Src-Dependent Mechanism in Breast Cancer Cells. <i>Molecular and Cellular Biology</i> , 2005, 25, 4826-4840.	2.3	113
3	Progesterone Receptor Induces ErbB-2 Nuclear Translocation To Promote Breast Cancer Growth via a Novel Transcriptional Effect: ErbB-2 Function as a Coactivator of Stat3. <i>Molecular and Cellular Biology</i> , 2010, 30, 5456-5472.	2.3	98
4	Progesterin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways. <i>Molecular Endocrinology</i> , 2007, 21, 1335-1358.	3.7	87
5	Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells. <i>Molecular and Cellular Biology</i> , 2003, 23, 1095-1111.	2.3	83
6	TNF $\alpha$ -Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 636-648.	7.0	74
7	Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. <i>Oncogene</i> , 2004, 23, 5161-5174.	5.9	66
8	p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. <i>Endocrine-Related Cancer</i> , 2013, 20, 197-212.	3.1	65
9	Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth. <i>Molecular and Cellular Biology</i> , 2009, 29, 1249-1265.	2.3	57
10	Targeting Stat3 Induces Senescence in Tumor Cells and Elicits Prophylactic and Therapeutic Immune Responses against Breast Cancer Growth Mediated by NK Cells and CD4+ T Cells. <i>Journal of Immunology</i> , 2012, 189, 1162-1172.	0.8	46
11	Molecular mechanisms underlying progesterone receptor action in breast cancer: Insights into cell proliferation and stem cell regulation. <i>Steroids</i> , 2019, 152, 108503.	1.8	41
12	Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. <i>BMC Cancer</i> , 2012, 12, 74.	2.6	38
13	Transactivation of ErbB-2 induced by tumor necrosis factor $\alpha$ promotes NF- $\kappa$ B activation and breast cancer cell proliferation. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 111-124.	2.5	35
14	Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. <i>Breast Cancer Research</i> , 2014, 16, 491.	5.0	27
15	Immunization with Murine Breast Cancer Cells Treated with Antisense Oligodeoxynucleotides to Type I Insulin-Like Growth Factor Receptor Induced an Antitumoral Effect Mediated by a CD8+ Response Involving Fas/Fas Ligand Cytotoxic Pathway. <i>Journal of Immunology</i> , 2006, 176, 3426-3437.	0.8	25
16	Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer. <i>Steroids</i> , 2011, 76, 381-392.	1.8	23
17	Progesterin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. <i>Steroids</i> , 2013, 78, 559-567.	1.8	22
18	Influence of conformationally restricted pyrimidines on the activity of 10 $\mu$ M DNAzymes. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2581-2586.	3.0	20

#	ARTICLE	IF	CITATIONS
19	Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. <i>BMC Cancer</i> , 2017, 17, 895.	2.6	20
20	Regulation of telomere homeostasis and genomic stability in cancer by <i>N<sup>6</sup></i> -adenosine methylation (m <sup>6</sup> A). <i>Science Advances</i> , 2021, 7, .	10.3	18
21	Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. <i>Oncimmunology</i> , 2020, 9, 1715767.	4.6	14
22	Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth. <i>Molecular Endocrinology</i> , 2015, 29, 1468-1485.	3.7	12
23	Revisiting progesterone receptor (PR) actions in breast cancer: Insights into PR repressive functions. <i>Steroids</i> , 2018, 133, 75-81.	1.8	12
24	Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis. <i>Hormones and Cancer</i> , 2020, 11, 218-239.	4.9	7
25	Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth. <i>Oncogene</i> , 2020, 39, 6245-6262.	5.9	5
26	The molecular basis of progesterone receptor action in breast carcinogenesis. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2012, 9, 105-17.	0.7	4
27	Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. <i>Cell Death and Disease</i> , 2022, 13, 447.	6.3	4
28	Steroid hormone receptors: A South American perspective. <i>Steroids</i> , 2020, 155, 108554.	1.8	0